174 related articles for article (PubMed ID: 3033468)
1. Incorporation of (E)-5-(2-iodovinyl)-2'-deoxyuridine into deoxyribonucleic acids of varicella-zoster virus (TK+ and TK- strains)-infected cells.
Yokota T; Konno K; Shigeta S; Verbruggen A; De Clercq E
Mol Pharmacol; 1987 May; 31(5):493-9. PubMed ID: 3033468
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of selective inhibition of varicella zoster virus replication by 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.
Yokota T; Konno K; Mori S; Shigeta S; Kumagai M; Watanabe Y; Machida H
Mol Pharmacol; 1989 Aug; 36(2):312-6. PubMed ID: 2549386
[TBL] [Abstract][Full Text] [Related]
3. Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene.
Balzarini J; De Clercq E; Verbruggen A; Ayusawa D; Shimizu K; Seno T
Mol Pharmacol; 1987 Sep; 32(3):410-6. PubMed ID: 2823092
[TBL] [Abstract][Full Text] [Related]
4. Highly selective cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine derivatives for murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 thymidine kinase gene.
Balzarini J; De Clercq E; Verbruggen A; Ayusawa D; Seno T
Mol Pharmacol; 1985 Dec; 28(6):581-7. PubMed ID: 3001499
[TBL] [Abstract][Full Text] [Related]
5. Role of the incorporation of (E)-5-(2-iodovinyl)-2'-deoxyuridine and its carbocyclic analogue into DNA of herpes simplex virus type 1-infected cells in the antiviral effects of these compounds.
Balzarini J; Bernaerts R; Verbruggen A; De Clercq E
Mol Pharmacol; 1990 Mar; 37(3):402-7. PubMed ID: 2156154
[TBL] [Abstract][Full Text] [Related]
6. Increased sensitivity of thymidine kinase-deficient (TK-) tumor cell lines to the cell growth inhibitory effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and related compounds.
Balzarini J; De Clercq E; Verbruggen A; Crumpacker C; Ayusawa D; Seno T
Anticancer Res; 1986; 6(5):1077-84. PubMed ID: 2432829
[TBL] [Abstract][Full Text] [Related]
7. Comparative inhibition of DNA polymerases from varicella zoster virus (TK+ and TK-) strains by (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-triphosphate.
Yokota T; Konno K; Shigeta S; De Clercq E
Mol Pharmacol; 1984 Sep; 26(2):376-80. PubMed ID: 6090888
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and cellular uptake of 2'-substituted analogues of (E)-5-(2-[125I]iodovinyl)-2'-deoxyuridine in tumor cells transduced with the herpes simplex type-1 thymidine kinase gene. Evaluation as probes for monitoring gene therapy.
Morin KW; Atrazheva ED; Knaus EE; Wiebe LI
J Med Chem; 1997 Jul; 40(14):2184-90. PubMed ID: 9216837
[TBL] [Abstract][Full Text] [Related]
9. Selective antiherpetic activity of carbocyclic analogues of (E)-5-(2-halogenovinyl)-2'-deoxyuridines: dependence on specific phosphorylation by viral thymidine kinase.
De Clercq E; Balzarini J; Bernaerts R; Herdewijn P; Verbruggen A
Biochem Biophys Res Commun; 1985 Jan; 126(1):397-403. PubMed ID: 2982373
[TBL] [Abstract][Full Text] [Related]
10. Isolation of drug resistant mutants of varicella-zoster virus: cross resistance of acyclovir resistant mutants with phosphonoacetic acid and bromodeoxyuridine.
Shiraki K; Ogino T; Yamanishi K; Takahashi M
Biken J; 1983 Mar; 26(1):17-23. PubMed ID: 6312958
[TBL] [Abstract][Full Text] [Related]
11. Deoxythymidine kinases in varicella-zoster virus infected and biochemically transformed cells.
Ogino T; Lopetegui P; Yamanishi K
Biken J; 1982 Sep; 25(3):149-56. PubMed ID: 6299267
[TBL] [Abstract][Full Text] [Related]
12. Novel (E)-5-(2-iodovinyl)-2'-deoxyuridine derivatives as potential cytostatic agents against herpes simplex virus thymidine kinase gene transfected tumors.
Balzarini J; Morin KW; Knaus EE; Wiebe LI; De Clercq E
Gene Ther; 1995 Jul; 2(5):317-22. PubMed ID: 7671107
[TBL] [Abstract][Full Text] [Related]
13. Differential metabolism of (E)-5-(2-iodovinyl)-2'-deoxyuridine (IVDU) by equine herpesvirus type 1- and herpes simplex virus-infected cells.
Kit S; Ichimura H; De Clercq E
Antiviral Res; 1987 Aug; 8(1):41-51. PubMed ID: 2825591
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a varicella-zoster virus variant with altered thymidine kinase activity.
Shigeta S; Mori S; Yokota T; Konno K; De Clercq E
Antimicrob Agents Chemother; 1986 Jun; 29(6):1053-8. PubMed ID: 3015014
[TBL] [Abstract][Full Text] [Related]
15. [Mechanisms of antiherpes drugs and drug resistant virus--effect of BVDU on varicella zoster virus replication].
Shigeta S; Yokota T
Rinsho Byori; 1985 Feb; 33(2):148-57. PubMed ID: 2987573
[No Abstract] [Full Text] [Related]
16. Analysis of mutations in the thymidine kinase gene of varicella zoster virus associated with resistance to 5-iodo-2'-deoxyuridine and 5-bromo-2'-deoxyuridine.
Kodama E; Mori S; Shigeta S
Antiviral Res; 1995 May; 27(1-2):165-70. PubMed ID: 7486953
[TBL] [Abstract][Full Text] [Related]
17. Selection of HSV-1 TK gene-transfected murine mammary carcinoma cells resistant to (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and ganciclovir (GCV).
Degrève B; De Clercq E; Balzarini J
Gene Ther; 2000 Sep; 7(18):1543-52. PubMed ID: 11021592
[TBL] [Abstract][Full Text] [Related]
18. Quantitative uptake studies of 131I-labeled (E)-5-(2-iodovinyl)-2'-deoxyuridine in herpes simplex virus-infected cells in vitro.
Gill MJ; Samuel J; Wiebe LI; Knaus EE; Tyrrell DL
Antimicrob Agents Chemother; 1984 Apr; 25(4):476-8. PubMed ID: 6732216
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.
De Clercq E; Descamps J; Ogata M; Shigeta S
Antimicrob Agents Chemother; 1982 Jan; 21(1):33-8. PubMed ID: 6282207
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase.
Grignet-Debrus C; Cool V; Baudson N; Degrève B; Balzarini J; De Leval L; Debrus S; Velu T; Calberg-Bacq CM
Cancer Gene Ther; 2000 Feb; 7(2):215-23. PubMed ID: 10770629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
